Labor Trade and Industry Minister Piyush Goyal on Friday called on the national pharmaceutical industry to strengthen its generic drugs sector and ensure a better link between entry and exit of products to become self-sufficient. Speaking at an event organized by the Indian Association of Drug Manufacturers to commemorate its Golden Jubilee celebrations here, Goyal also called on the industry to plan for the long term to meet the challenges associated with the global supply chain.

“The phenomenal growth we have experienced over the past decade must be continued to ensure we become self-sufficient. Global supply chains are becoming increasingly difficult to predict. The challenges are becoming unimaginably severe,” said he declared.

In this situation, the Minister said, “it is extremely important that we not only focus on our strengths in the generics sector, but also on our backward and forward links”.

“We need to plan for the long term to become increasingly self-sufficient and with that we will go out into the world with the confidence of a powerful nation, engaging with the world as equals for a better future for our industry. “, said Goyal. said, adding that India’s goal should be to become the healthcare guardian of the world.

Emphasizing the need for mutual support within the industry, the minister said: “Each country protects its main industry and I think our main industry is the pharmaceutical industry.”

Goyal also mentioned government measures such as the production-related incentives program for the manufacture of active pharmaceutical ingredients and medical devices and said, “I hope many manufacturers in the pharmaceutical industry take advantage of this program”.

It is important for the industry to try to develop products and innovate in medical research, he said.

“Our international competitiveness should be very important to keep us abreast of new developments and good manufacturing practices,” he added.

He also said that the government’s efforts to strike free trade agreements with different countries will create avenues for easier approvals of Indian pharmaceuticals across the world.